导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.84% | 3957/4773 |
| 近一周 | -3.20% | 3878/5462 |
| 近一月 | -3.28% | 1670/5421 |
| 近一季 | -1.97% | 1118/5209 |
| 近半年 | -5.32% | 2821/4920 |
| 近一年 | -16.15% | 3761/4366 |
| 近两年 | 29.04% | 2315/2954 |
| 近三年 | 9.39% | 1757/2253 |
| 成立以来 | -30.50% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.49% 4661/4961 |
8.74% 2551/5312 |
- - |
- - |
| 2025 | 3.41% 3125/4813 |
-6.77% 3395/3635 |
4.18% 837/4076 |
10.87% 3231/4524 |
-3.97% 3367/4813 |
| 2024 | 28.19% 162/3463 |
-4.85% 1779/2808 |
-8.19% 2180/3014 |
42.96% 33/3129 |
2.64% 915/3463 |
| 2023 | 3.58% 272/2656 |
3.85% 1108/2280 |
-2.83% 684/2385 |
7.37% 45/2515 |
-4.40% 1008/2655 |
| 2022 | -24.92% 1271/2207 |
-17.80% 1265/1919 |
1.92% 1400/2016 |
-15.34% 1270/2113 |
5.86% 422/2208 |
| 2021 | -2.82% 873/1822 |
-14.32% 1172/1255 |
6.76% 721/1330 |
4.42% 352/1466 |
1.74% 816/1822 |
| 2020 | 17.34% 764/1250 |
-10.52% 784/1022 |
8.96% 803/1060 |
18.74% 71/1152 |
- - |
| 2019 | 41.09% 238/1092 |
44.89% 23/748 |
-6.82% 521/797 |
-4.74% 779/844 |
9.71% 200/912 |
| 2018 | -23.92% 307/834 |
- - |
- - |
- - |
-1.70% 20/691 |
| 2017 | -11.73% 546/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.91% 404/605 |
- - |
- - |
- - |
- - |
| 2015 | -29.01% 305/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证全指证券公司指数(LOF)A VS. 长安沪深300非周期A(740101) |